SEC Filing Summary: Park Ha Biological Technology Co., Ltd.
Business Context and Reporting Period
This Form 6-K filing covers the month of August 2025 for Park Ha Biological Technology Co., Ltd., a foreign private issuer headquartered in Wuxi, Jiangsu Province, People's Republic of China. The report is filed pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
The primary material change disclosed is the resignation of Mr. Da Yang as an independent director, effective August 25, 2025. The Company explicitly states that this resignation was not the result of any disagreement with the Company's operations, policies, or procedures.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, or specific risks beyond the personnel change. No unusual items or contingencies are reported in this document.
Investor Verification Checklist
- Confirm the effective date of Mr. Da Yang's resignation (August 25, 2025).
- Verify the Company's statement that the resignation was not due to any disagreement.
- Monitor subsequent filings for the appointment of a replacement independent director.
- Review the Company's most recent Form 20-F for the latest financial performance data, as this 6-K does not include financial metrics.